MindMed Q3 net loss $17.9M; cash $117.7M; Phase 2b GAD topline expected Q4 2023

Definium Therapeutics, Inc.

2023-Q3 EPS reported -$1.85

Cash and cash equivalents $117.7M at Sept 30, 2023; expected to fund operations into 2026.
Net loss $17.9M in Q3 2023 vs $16.5M in Q3 2022; R&D expenses rose to $13.2M from $7.8M.
Phase 2b study of MM-120 in GAD (198 participants) topline results expected in Q4 2023.
Phase 2a proof-of-concept study of MM-120 in ADHD (53 participants) topline data expected Q1 2024.
Initiation of Phase 1 study of MM-402 for ASD expected in Q4 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Definium Therapeutics, Inc. reported the quarter ended September 30, 2023 results: net income Net loss for the quarter ended September 30, 2023, was $17.9 million.

Period: the quarter ended September 30, 2023
Net income: Net loss for the quarter ended September 30, 2023, was $17.9 million
Result: reported results

Exact text from the filing

Net loss for the quarter ended September 30, 2023, was $17.9 million, compared to $16.5 million for the same period in 2022.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Definium Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-058230

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.